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PIK3CA-related overgrowth spectrum (PROS) encompasses a range of debilitating
conditions defined by asymmetric overgrowth caused by mosaic activating PIK3CA
variants. PIK3CA encodes the p110α catalytic subunit of phosphatidylinositol-3-
kinase (PI3K), a critical transducer of growth factor signaling. As mTOR mediates
the growth-promoting actions of PI3K, we hypothesized that the mTOR inhibitor
sirolimus would slow pathological overgrowth.
Methods
Thirty-nine participants with PROS and progressive overgrowth were enrolled into
open-label studies across three centers, and results were pooled. For the primary
outcome, tissue volumes at affected and unaffected sites were measured by dual
energy X-ray absorptiometry during 26 weeks of untreated run-in and 26 weeks of
sirolimus therapy.
Results
Thirty participants completed the study. Sirolimus led to a change in mean
percentage total tissue volume of –7.2% (SD 16.0, p = 0.04) at affected sites, but not
at unaffected sites (+1.7%, SD 11.5, p = 0.48) (n = 23 evaluable). Twenty-eight of 39
(72%) participants had ≥1 adverse event related to sirolimus of which 37% were
grade 3 or 4 in severity and 7/39 (18%) participants were withdrawn consequently.
Conclusion
This study suggests that low-dose sirolimus can modestly reduce overgrowth, but
cautions that the side-effect profile is significant, mandating individualized











































Publié sur Okina (http://okina.univ-angers.fr)
